VivoSim Labs is a pharmaceutical and biotech services company that tests drug candidates using 3D human tissue models of the liver and intestine. These models mimic the architecture and function of human tissue to help drug developers identify toxicity or intestinal side effects before starting clinical trials. The company's core product is the NAMkind liver platform, which screens for drug-induced liver injury. VivoSim pivoted to this services-based model in 2025 after selling its legacy clinical-stage drug program to Eli Lilly. VivoSim generates revenue by selling testing and research services directly to pharmaceutical and biotech clients. Revenue depends on the number and scope of client engagements and the integration of these models into standard development workflows. Beyond liver toxicology, the company offers intestinal tolerability testing and bespoke mechanism-of-action studies. VivoSim operates as an early-stage commercial business and maintains a portfolio of over 160 patents covering 3D bioprinting and tissue design. This intellectual property protects the company's service offerings and generates licensing revenue. VivoSim anticipates that its growth will be supported by a regulatory shift away from animal testing requirements toward human-relevant models.